Death · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
PEG interferon alpha‐2a · patients on HD with HCV infection
High showed no clear difference in PEG interferon alpha‐2a compared with low dose pegylated interferon alpha‐2a or alpha‐2b (low certainty).
4 findings from 1 review
RR 5.66 [0.69, 46.31]
1 study · 81 participants
Low
RR 1.12 [0.4, 2.21]
1 study · 43 participants
Low
RR 1.19 [0.79, 1.78]
1 study · 81 participants
Low
Show 1 more finding
PEG interferon (alpha‐2b) · patients on HD with HCV infection
High showed no clear difference in PEG interferon alpha‐2b compared with low dose pegylated interferon alpha‐2a or alpha‐2b (low certainty).
2 findings from 1 review
PEG interferon (combined) · patients on HD with HCV infection
High showed no clear difference in PEG interferon (combined) compared with low dose pegylated interferon alpha‐2a or alpha‐2b (moderate certainty).
3 findings from 1 review
RR 4.3 [0.76, 24.33]
2 studies · 97 participants
Moderate
RR 1.12 [0.4, 2.21]
1 study · 43 participants
Low
RR 1.05 [0.61, 1.83]
2 studies · 97 participants
Moderate
End‐of‐treatment response · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment discontinuation · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Circuit lifespana · AKI patients receiving CKRT
1 finding from 1 review
Death from any cause at day 28 of · AKI patients receiving CKRT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recovery of kidney function · AKI patients receiving CKRT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Vascular access complications · AKI patients receiving CKRT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospital stay — not reported · patients requiring haemodialysis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dialysis dysequilibrium syndrome · patients requiring haemodialysis
It is very uncertain whether summary of findings table ‐ High sodium dialysate changes dialysis dysequilibrium syndrome compared with standard sodium dialysate (very low certainty).
1 finding from 1 review
Severe dialysis dysequilibrium syndrome · patients requiring haemodialysis
It is very uncertain whether summary of findings table ‐ High sodium dialysate changes severe dialysis dysequilibrium syndrome compared with standard sodium dialysate (very low certainty).
1 finding from 1 review
Death · patients requiring haemodialysis
1 finding from 1 review
Adverse events · patients requiring haemodialysis
It is very uncertain whether summary of findings table ‐ High sodium dialysate changes adverse events compared with standard sodium dialysate (very low certainty).
1 finding from 1 review